Clinical Trials Logo

Clinical Trial Summary

This study will evaluate safety and tolerability to determine the Maximum tolerated dose (MTD) and/or Recommended dose (RD).


Clinical Trial Description

This is a multi-center, open label, dose finding, phase I study of oral single agent BGJ398, administered on a continuous once and/or twice daily schedule. ;


Study Design


Related Conditions & MeSH terms

  • Tumor With Alterations of the FGF-R

NCT number NCT01697605
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 1
Start date October 19, 2012
Completion date February 7, 2019